

ASX ANNOUNCEMENT

AGM Chairman's address and CEO presentation

Melbourne, Australia; 29 November 2016: Attached is the Chairman's address together with the CEO's presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 3.00pm today.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP® drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell's Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, Manix®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

For more information please visit: www.starpharma.com

FOR FURTHER INFORMATION

Media:

WE Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma:
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary

+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Chairman's Address

Starpharma Holdings Limited

Annual General Meeting

29 November 2016

Good afternoon and welcome to Starpharma's Annual General Meeting for 2016.

Our last financial year saw further significant progress across our portfolio and it is now very clear that Starpharma's dendrimer based products have the potential to play an important role in the global health industry. We have a highly compelling and diverse range of differentiated products across sexual health, women's health, cancer and crop protection, generating significant interest from commercial partners and investors around the world.

Starpharma is one of Australia's most innovative biotechnology companies. Our achievements this year across the VivaGel® portfolio, DEP® drug delivery and agrochemicals highlight the strength of our business strategy and the confidence our partners have in our technology and our team. In particular, this year was a milestone year with respect to striking important commercial deals and achieving key regulatory goals.

We signed a multiproduct license with AstraZeneca for the commercialisation of DEP® drug delivery products in September last year and we already have two compounds under development under this license. Encouragingly, based on a broader review of DEP® within AstraZeneca, in July this year AstraZeneca and Starpharma initiated a further, development program outside the licensed field which will see the application of Starpharma's DEP® platform to a completely unrelated compound from AstraZeneca's portfolio. These three parallel programs are progressing extremely well and the rapid expansion shows a strong vote of confidence from a global company like AstraZeneca in our DEP® technology.

AstraZeneca's strong interest in cancer is well documented and the benefits of DEP® in this setting are gaining recognition both inside AstraZeneca and beyond. Our DEP® platform enables companies not only to improve their products but also gain enhanced and extended patent protection, which is a very valuable feature. For Starpharma's shareholders, the almost infinite opportunities associated with DEP® technology means it has the potential to yield many diverse income streams through partnerships with pharmaceutical companies, such as AstraZeneca, as well as internally funded programs such as DEP® docetaxel and DEP® cabazitaxel.

The phase 1 study for DEP® docetaxel – the company's dendrimer-enhanced version of anticancer chemotherapy drug Taxotere® - is now in the final stages of enrolment, and the clinical data is very encouraging. Not only have cancer patients experienced no neutropenia and no hair loss, but a significant portion of patients have also shown positive efficacy signals and anticancer activity.

We are also seeing exciting data for our Targeted DEP® conjugates and DEP® cabazitaxel internal programs.

In our VivaGel® portfolio, we signed a license and supply agreement with Aspen Pharmacare for the sales and marketing for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis in Australia and New Zealand and our product launch preparations are now well advanced with the launch due in the near future. BV is the most common vaginal infection worldwide, causing a range of serious medical issues for sufferers, and is an area of significant unmet medical need. The current market for products in this vaginosis 'treatment' category is estimated to be in excess of US$750 million globally.

Commercial deals for this product are actively being negotiated abroad, particularly in Europe, where we have been granted EU marketing approval. This approval, a critical milestone, allows VivaGel® BV to be marketed in the European Economic Area, which includes the 28 countries of the EU plus the European Free Trade Association will also accelerate the approval processes within countries that recognise EU approval.

In our other VivaGel® BV product - for the prevention of recurrent BV - we have now completed recruitment of our two pivotal Phase 3 parallel trials, which are being conducted in the US, Europe, Asia and Mexico. We expect trial completion during the first quarter of 2017, with results to be announced in the second quarter.

There are no approved products for this chronic condition of recurrent bacterial vaginosis. The unmet need is significant, with the global market estimated to be worth around $1 billion annually.

In the VivaGel® condom product area, we signed a commercially important deal with Chinese company Shenyang Sky and Land Latex Co. for the manufacture and sale of VivaGel® condoms for the Chinese Government Sector. The Chinese government provides around 3 billion condoms per annum to the public through various initiatives and Shenyang are a major supplier. This new license in the world's most populous country opened up a market segment for the Company not captured by its other licenses. Just yesterday, we announced another deal for the VivaGel® condom, for the Iranian market.

During the year, we received regulatory approval in the Canadian market, our first North American approval for the VivaGel® condom. Starpharma's marketing partner, Ansell, plans to launch the condoms in Canada under the LifeStyles® Dual Protect™ brand early in the New Year.

In our agrochemical portfolio, 2016 marked the licensing of Starpharma's Priostar® dendrimer technology to Adama for the development and commercialisation of enhanced, proprietary 2,4-D products for the US market. Adama is one of the world's leading crop protection companies, and 2,4-D is one of the top three herbicides sold in the world. It is a highly competitive market and the Priostar® enhanced products offer a range of important performance advantages.

The market for yield-improving agrochemicals is growing and it's unsurprising to see that the industry's biggest players have been consolidating their positions. Following a recent corporate transaction, Adama is now owned outright by ChemChina, who has a reverse merger with its subsidiary planned and a possible listing on the Shenzhen Stock Exchange.

The foundations of a successful company in this industry is a combination of superior products, strong commercial partnerships, and the ability to continually achieve the right level of funding and investor mix, and strong management and leadership. Given the broad applicability of our platform, we also have so much potential to expand our product development and commercial collaborations.

Starpharma's strong cash balance and capital raising - combined with prudent cash flow management - have all helped fund and secure both existing and new programs. We continue to attract major investors in Australia, Europe, Asia and the US.

I'd like to take this opportunity to thank our Chief Executive Officer, Dr Jackie Fairley, the executive management team and the whole Starpharma staff for their dedication and passion for our business. Starpharma is in the fortunate position of having a committed and highly skilled team with a sharp focus on maximising the commercial potential of our products and the dendrimer platform. I would also like to thank my fellow Board members for their contributions and expertise through the year. Our team has the clear objective to produce innovative products and superior returns from our technology for our shareholders and the wider society.

In terms of the year ahead, we are excited about the commercial momentum building for our compelling products. Starpharma is on the cusp of several catalysts – not least of which is the market launch of VivaGel® for BV treatment, rolling out our condoms internationally, and nearing significant value-creating clinical milestones for both DEP® Docetaxel and VivaGel® for prevention of recurrent BV. We thank you, our shareholders, for your support - as we drive forward what will be a commercially transformational year for Starpharma.

Thank you,

Rob Thomas, AM, Chairman.



starpharma

STARPHARMA HOLDINGS LIMITED
ASX:SPL; OTCQX:SPHRY

AGM 2016
CEO Presentation

29 November 2016

Important notice and disclaimer

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Overview: Starpharma Holdings Limited (ASX:SPL)

- **Melbourne-based ASX300 company; Market Cap ~A$250M**
- **Unique proprietary polymer (dendrimer) platform**
- **Deep portfolio of products targeting three large, high-value markets**
- **Proven track record of commercialisation - the VivaGel® condom in-market & with two other products in late stage development or awaiting launch**
- **Successful global partnerships in place, creating significant optionality, accelerating path to market & managing investment risk**
- **Well-funded, with cash reserves of $37.6M (30 Sept. 2016)**









Starpharma's headquarters and laboratories
Melbourne, Australia

Global Leader in Dendrimer Products

Starpharma's products, programs and commercial partnerships with leading companies

Starpharma's Dendrimer Platform ~120 granted patents

VivaGel® Portfolio

- VivaGel® Condom
  - Ansell
  - okamoto
  - SKY & LAND
  - Koushan Pharmed
- VivaGel® BV (bacterial vaginosis)
  - VivaGel® BV Treatment & Symptom Relief
  - VivaGel® BV Prevention of Recurrence
  - aspen AUSTRALIA

DEP® Drug Delivery

- Internal DEP® Programs
  - DEP® docetaxel
  - Other DEP® cabazitaxel, irinotecan, Targeted, oxaliplatin etc.
- Partnered DEP® Programs
  - companies including AstraZeneca
  - several undisclosed partnerships with leading Pharma companies

Agrochemicals

- Priostar® Improved Formulations
  - glyphosate
  - glufosinate ammonium
  - & others
- Partnered Priostar® Programs
  - companies including ADAMA, Gowan The Go To Company, ISAGRO

Year in Review

September 2015

Multiproduct DEP® license; AZ elects first candidate for development

September 2015

EU Marketing Approval Granted for VivaGel® BV

October 2015

Additional US VivaGel® patent

November 2015

Targeted DEP® outperforms leading treatments in ovarian cancer model

December 2015

Second AZ DEP® candidate elected

December 2015

$34 million capital raising
(incl. $2M SPP in Jan '16)

December 2015

MOU signed in China for VivaGel® condom



March 2016

License to Aspen for sales & marketing of VivaGel® BV in ANZ

March 2016

License to Adama for Priostar® for novel 2,4-D products in US

April/May 2016

DEP® cabazitaxel shows complete and sustained tumour regression in breast cancer model & no neutropenia

May 2016

VivaGel® shows potent activity against Zika virus



July 2016

License to supply VivaGel® condom to Chinese Government market

July 2016

Additional AstraZeneca program to develop a further product from its portfolio

September 2016

VivaGel® condom approved in Canada

October 2016

Enrolment complete: phase 3 trials for VivaGel® BV prevention of recurrence



Key financials FY 2016

- **Total revenue and other income $4.6M (+173% - includes first US$2M DEP® AZ milestone)**
- **Cash Burn $17.5M (increased due to significant clinical programs in FY2016)**
- **Net proceeds of $32.6M from equity placement and SPP**
- **Cash at year end $46.0M**



Key Financial Data	FY 2016 AUD $M	FY 2015 AUD $M
Total revenue & other income	4.6	1.7
R&D Tax Incentive	3.5	3.5
Net loss after tax	(22.7)	(19.0)
Net Cash Burn[1]	(17.5)	(13.7)
Closing Cash[2] (30 June)	46.0	30.8

[1] Net cash burn is considered a non-IFRS value and has not been audited in accordance with Australian Accounting Standards. Net cash burn is calculated by the movement in cash and cash equivalents at 30 June of the applicable year adjusted for net proceeds on the issue of any equity

[2] Cash at 30 Sep 2016 of $37.6M

Pipeline and Developments



starpharma

DEP® Drug Delivery



DEP® Drug Delivery

Dual Strategy

Provides technical, IP and financial leverage
Increases commercial opportunities
Reduces invested capital
De-risks



Internal Programs

- Application to established drugs
- New patents based on DEP® provide patent life extension
- Self funded
- Return through licensing milestones and royalties (e.g. DEP® docetaxel)



Partnered Programs

- Application to partners' drugs (typically proprietary)
- Platform with broad optionality
- New patents based on DEP® provide patent life extension (life-cycle management)
- Funded development
- Return through licensing milestones and royalties (e.g. AstraZeneca)

Benefits of DEP®

- Improved efficacy
- Reduced toxicity
- Improved pharmacokinetics
- Improved solubility
- New patents based on DEP®

Extensive partner engagement to maximise commercial outcomes

DEP® Platform - Multiple and reproducible benefits demonstrated in internal and partnered programs

starpharma



In multiple programs* DEP® has demonstrated:

- **a reduction or elimination of dose-limiting toxicities**
- **significantly improved anticancer efficacy**
- **an expanded therapeutic window**
- **extended plasma half-life**
- **significant formulation enhancements (including detergent removal)**

*** Demonstrated in internal and partnered (e.g. AstraZeneca and other) programs**



DEP® allows targeting of drugs to cancer tissue resulting in higher tissue levels – for DEP® docetaxel up to 70x more than Taxotere®

AstraZeneca multiproduct license and new program – Partnered DEP® momentum building


starpharma

ASX ANNOUNCEMENT

Starpharma signs drug delivery license with AstraZeneca

- AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound on signature, and with potential for follow on compounds directed at a defined family of targets.
- Under the agreement Starpharma will receive a signature payment of US$2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP® product of USD$124 million (A$177 million).
- Subsequent qualifying products successfully developed and commercialised to specified annual sales levels could yield up to USD$93.3 million (A$133 million) in milestone payments per product.
- In summary, signature and milestone payments could total USD$126 million (A$180 million) for the first AstraZeneca DEP® product and up to USD$93.3 million (A$133 million) for each subsequent qualifying product.
- Any AstraZeneca DEP® products would also attract tiered royalties on net sales.
- AstraZeneca will fund all development and commercialisation costs for AstraZeneca DEP® products under the agreement.

- AZ multiproduct license for use of DEP® delivery platform for the development and commercialisation of proprietary AZ compounds directed at a defined family of targets
- SPL eligible to receive development, launch and sales milestones for the first AZ DEP® product of up to USD$126m plus royalties & up to USD$93m in milestones for each subsequent qualifying AZ DEP® products
- Tiered royalties on net sales
- AZ funds all development and commercialisation costs
- Received US$2M in H1 FY2016
- Starpharma's internal products not impacted and agreement allows for multiple other DEP® licences
- Two new AZ programs added since signature

AstraZeneca

"SPL estimates that each product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more."



"We already have a long-standing and successful working relationship with Starpharma. This license agreement will enable us to further harness the DEP® technology and evaluate its potential across novel molecules within our oncology portfolio."

Dr Susan Galbraith,
Head of the Oncology Innovative Medicines Unit at AstraZeneca

AstraZeneca multiproduct license and new program – Partnered DEP® momentum building



" AstraZeneca has a deep-rooted heritage in Oncology..
The Company is committed to advancing New Oncology as one of AstraZeneca's Growth Platforms…..

In addition to core capabilities, the Company is actively pursuing innovative collaborations and investments that accelerate the delivery of AstraZeneca's strategy…."

AstraZeneca
Q3 Results Presentation
November 2016

Starpharma's AstraZeneca deal structure provides for significant optionality – with multiple DEP® products in development and the potential for many other partnerships



DEP® Docetaxel: Multiple benefits

- Docetaxel (Taxotere®) is a blockbuster cancer drug **Sales: US$3.1B (2012)**
- Docetaxel is used in major cancer types including breast, prostate, lung and ovarian cancer
- Starpharma's patented DEP® docetaxel is a nanoparticle formulation with **multiple advantages compared to Taxotere®**
- **DEP® patents and applications provide coverage to 2032**
- **DEP® docetaxel Phase 1 trial – no neutropenia, no hair-loss, and promising efficacy signals**

DEP® docetaxel vs. Taxotere®

1. Elimination of major dose-limiting side effect (neutropenia)
2. Detergent-free formulation (less toxic)
3. Tumour-targeting (~70x more)
4. Extended duration (half-life)
5. Improved efficacy (breast, ovarian, prostate)



DEP® docetaxel

DEP® Docetaxel Clinical Program

Phase 1 Clinical Trial (open label study - 25-30 cancer patients - various solid tumours)
Phase 2 Clinical Trial (in advanced planning)

Current Status:
- Final phase of enrolment underway; >80% recruited
- Large UK site recently opened to:
  - enrich final patient cohort with specific tumour types and
  - facilitate transition to Phase 2



Patients treated with DEP® docetaxel have exhibited:

- **No neutropenia** (docetaxel dose limiting toxicity)
- **No alopecia** (hair loss) reported
- **No hypersensitivity**
- **No standard steroid pre-treatment required**

Encouraging efficacy signals in a significant proportion of patients including:

- in **pancreatic** (SD*>20 wks), **oesophageal** (SD >18 wks), **prostate, lung, H&N and brain tumours**
- at low doses, **in cancers not responsive to docetaxel** and in a heavily pre-treated patient cohort

* Stable Disease

Phase 2:
- Planning now well advanced including CRO, trial design, KOLs and trial material manufacture

PROPOSED PHASE 2 STUDY (in advanced planning)

- Two-stage study design proposed
- Objective to establish anti-tumour activity and safety of DEP® docetaxel
- Open label, N=40 (e.g. 20+20)
- Two-stage approach:
  - Stage 1 – patients with cancer types based on standard docetaxel indications e.g. lung, prostate, pancreatic (taking account of phase 1 efficacy signals)
  - Stage 2 – select cancer type based on efficacy signals observed in Stage 1
- Standard efficacy endpoints



DEP® Cabazitaxel: Multiple benefits

About cabazitaxel (Jevtana®)

- **2014 sales: US$427m (est. US$500m by 2018)**
- **Primary indication – Prostate cancer**
- **In clinical development for other cancers including Breast, Bladder, Head & Neck**
- **Dose Limiting Toxicity – neutropenia (FDA "Black Box" warning)**
- **FDA "Black Box" warning due to anaphylaxis (polysorbate 80 detergent)**

DEP® cabazitaxel

- ✓ **Significantly enhanced efficacy versus Jevtana® (cabazitaxel) in mouse xenograft models of breast and prostate cancer**
- ✓ **Detergent (polysorbate 80) free formulation**
- ✓ **Lack of neutropenia**
- ✓ **Final pre-clinical studies in progress; preparations underway for clinical trial commencement in 2017**

DEP® cabazitaxel





DEP® Platform - highly reproducible benefits

DEP® benefits as seen in preclinical studies with DEP® docetaxel and DEP ® cabazitaxel

Improved Efficacy



DEP® docetaxel



DEP® cabazitaxel

Mouse xenograft models using MBA-231 DEP® conjugate vs original – P<0.01 for both docetaxel and cabazitaxel

Improved Safety



DEP® docetaxel



DEP® cabazitaxel

Lack of neutropenia – the DLT for both docetaxel and cabazitaxel – as seen with DEP ® conjugates in rat model

Improved Survival



DEP® docetaxel



DEP® cabazitaxel

Kaplan Meier survival curves DEP ® conjugate vs original – P<0.001 for both docetaxel and cabazitaxel

Starpharma's DEP® Irinotecan

- **Irinotecan (Camptosar®) is a major cancer drug primarily used for the treatment of advanced colorectal cancer (peak sales US$1.1B)**
- **Colorectal cancer is one of the most common cancers and an area of significant unmet need with few treatment options**
- **Irinotecan has FDA "Black Box" warnings for - severe diarrhoea, myelosuppression and neutropenia**
- **DEP® Irinotecan incorporates an irinotecan derivative (SN-38) and shows enhanced tumour growth inhibition compared to Irinotecan and near-complete tumour regression**

Interim Results: Efficacy of DEP® Irinotecan vs Irinotecan in human Colon Cancer Model*





** SW620 (colon cancer) mouse xenograft Balb/c nude mice (n=6 /group). Mice were dosed IV with Vehicle, DEP® Irinotecan or Irinotecan on days 1, 8 and 15.*

Targeted DEP® outperforms leading treatments in Ovarian Cancer Model

Targeted DEP®

Efficacy of HER2-targeted DEP® Conjugate vs Kadcyla® and Herceptin® in an Ovarian* Cancer Model



*SKOV-3 Ovarian cancer xenograft in NOD-SCID mice (5-6/group) Saline, Kadcyla® (10mg/kg) and Targeted DEP® conjugate were dosed once/wk for 3 wks; Herceptin® (20mg/kg) dosed twice/wk for 3 wks.

Statistical analysis at day 40. Kadcyla® vs Targeted DEP®; P<0.0001 (ANOVA followed by Tukey's post hoc test).

- **SPL's novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model**
- **The antibody-targeted DEP® conjugate (using Herceptin as the targeting group) significantly outperformed both Roche's Kadcyla® (T-DM1) and Herceptin® alone**
- **2 targeted DEP® partnerships signed with major players' antibody-drug-conjugates**

Kaplan Meier Survival Curve





starpharma

VivaGel®

VivaGel® BV

VivaGel® Condom

VivaGel® Portfolio

- **VivaGel® is a proprietary antimicrobial dendrimer active in HIV, HSV, HPV and bacterial vaginosis (BV)**
- **VivaGel® BV is under development for two BV indications – Treatment of BV and Prevention of Recurrent BV**
  - **Treatment is approved in EU, ANZ license signed with launch in the near future - advanced commercial negotiations underway in multiple international territories including Europe**
  - **Prevention of Recurrent BV (R-BV) – Phase 3 clinical program nearing completion (under SPA)**
- **VivaGel® (antiviral) condom rights licensed to Ansell and Okamoto; launched in Australia, recently approved in Canada and regulatory processes underway in other regions**
- **VivaGel® condom license signed with Sky & Land for supply to the Chinese Government market and Koushan for Iran**



VivaGel® Condom: A compelling World-First Product



starpharma



THE WORLD'S FIRST ANTI-VIRAL CONDOM

- Typical condom use associated with estimated: ~80% reduction in HIV, 30% reduction in genital herpes (HSV-2) and ~70% reduction in risk of HPV infection
- VivaGel® Condom: contains the potent antiviral and reduces risk of exposure to viruses via viral inactivation -- VivaGel® shown in laboratory studies to inactivate up to 99.9% HIV, HPV & HSV-2 & near complete antiviral protection against Zika virus
- VivaGel® condom has been licensed to market leaders:
  - Ansell – No. 2 globally
  - Okamoto – No. 1 in Japan (#4 globally)
  - Shenyang Sky and Land a leading supplier to Chinese Government Market
  - Koushan Pharmed for Iran
- Marketed by Ansell under LifeStyles® Dual Protect™ brand (approved in Australia, NZ, Canada with advanced regulatory processes in other regions)
- Launch of LifeStyles® Dual Protect™ in Canada scheduled for early CY 2017
- Branded global condom market: $1.1B
- VivaGel® condom patent protection up to 2028

DUAL PROTECT™ with VivaGel® : lubricated with VivaGel® which has been shown to inactivate up to 99.9% HIV, HPV and HSV (Herpes) in laboratory studies

Koushan Pharmed

SKY & LAND SHENYANG SKY & LAND LATEX CO.,LTD.

okamoto®

Ansell

VivaGel® Condom license for the Chinese Government Market

- Exclusive license and supply agreement signed with Shenyang Sky and Land Latex Co. Ltd. for manufacture and sale of VivaGel® condoms to the Chinese Government market (July 2016)
- New market opportunity for VivaGel® condoms
- Sky and Land is a major provider of condoms to the Chinese Government (annual requirement ~ 3 billion condoms)



Starpharma 签署 VivaGel®避孕套在中国的授权

澳大利亚墨尔本--(BUSINESS WIRE)--(美国商业资讯) -- 澳大利亚生物科技公司 Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) 七月二十一日宣布，与沈阳天地乳胶有限公司（天地公司）签署排他性授权和供货协议，面向中国避孕套市场的政府细分市场生产和销售 VivaGel®避孕套。该协议之前，Starpharma 于 2015 年 12 月与天地公司签署了谅解备忘录。

天地公司是一家拥有多元化业务的中国公司，在中国拥有并运营多家避孕套生产工厂。该公司是面向中国政府的主要避孕套供应商，中国政府通过若干项目向其公民提供避孕套，每年约需要 30 亿只避孕套。



Bacterial Vaginosis and VivaGel® BV: Two Attractive Commercial Opportunities

Bacterial Vaginosis (BV):

- Most common vaginal infection worldwide
- ~29% women infected in US; up to 51% in some groups
- Current therapies have low cure rates and nasty side effects
- Recurrent BV (R-BV) occurs in 50-60% of BV sufferers
- No approved products for Recurrent BV (R-BV)

Large market opportunity for both prevention of R-BV and BV Treatment & Symptom Relief



* Estimate – Global Data, IMS, various Industry reports

Bacterial Vaginosis (BV) is the most common vaginal infection worldwide, twice as common as thrush…



VivaGel® BV: Product Proposition

- a non-antibiotic therapy
- treatment and management of BV symptoms *and* prevention of R-BV
- a selective antimicrobial effect for pathogens that cause BV
- a local effect and is not systemically absorbed
- bio-adhesive properties

VivaGel® BV: Two Attractive Commercial Opportunities



VivaGel® BV Treatment & Symptom Relief

- Acute use product
- Global market est. >US$750 M
- EU marketing approval achieved – Treatment of BV, including rapid relief of BV symptoms
- Regulatory approval underway in multiple regions
- Licensed to Aspen for ANZ
- Multiple well-advanced partnering discussions underway (regional & global)
- Commercial manufacture underway and launch planned in the near future
- Recent FDA Guidance opens up a significant new market opportunity; NDA planning underway

VivaGel® BV Prevention of recurrence

- Chronic use product
- Unmet need: no approved products for R-BV
- Global market est. >US$1 B
- ~60% BV sufferers experience recurrence
- SPA agreement with FDA in place
- Phase 3 program 100% recruited (Results Q2 CY17)
- Partnering discussions underway
- NDA planning underway

Benefits of VivaGel®

- Rapid resolution of symptoms
- Non-antibiotic
- Not systemically absorbed
- Selective antimicrobial effect
- Excellent tolerability

Advanced licence negotiations underway for multiple regions

Current treatments for Bacterial Vaginosis (BV) are inadequate…



"***In my medical practice I see many people who have repeatedly failed conventional treatment with metronidazole"***

"current treatments do not offer long term cure for BV and cure rates are poor"

"Our ability to prevent recurrent BV with current treatment regimes is abysmal"

"There is an enormous need for a safe and effective treatment to prevent recurrence of BV in women suffering BV"

Professor J Sobel
ID Physician & KOL
Dean, Wayne State University School of Medicine

Current treatment options

- Antibiotics – metronidazole or clindamycin
- pH Modifiers – lactic acid, ascorbic acid
- Probiotics – lactobacillus
- Antiseptics – Povidone-iodine

Limitations

- ✕ Significant side effects (GI effects, nausea, metallic taste, cause thrush)
- ✕ Lack of clinical efficacy data
- ✕ Recurrence rates are high
- ✕ Drug resistance is an issue
- ✕ Significant Quality of Life impact (no alcohol, contraceptive restrictions)
- ✕ No approved product for prevention of recurrence
- ✕ OTC products have limited efficacy and clinical data

VivaGel® BV – A breakthrough product for BV

A new approach to the treatment of BV, management of symptoms and prevention of BV recurrence

VivaGel® BV: key features

- ✓ **Treatment of BV**
- ✓ **Rapid resolution of symptoms**
- ✓ **Selective effect on pathogens that cause BV**
- ✓ **Local effect, not systemically absorbed**
- ✓ **Normalises vaginal pH**
- ✓ **Excellent tolerability**
- ✓ **Significant supporting clinical data**
- ✓ **Proprietary IP position**

First product developed specifically for women who suffer from BV

Patient Benefits

- ✓ Topical
- ✓ Bioadhesive
- ✓ Clear gel
- ✓ No fragrance
- ✓ Water-based
- ✓ Convenient to use
- ✓ No lifestyle impacts



Fleurstat™ is a Trademark of Aspen Pharmacare Australia Pty Ltd

VivaGel® BV inhibits biofilms - a novel mechanism and expanded commercial opportunity

- **Recent studies show that VivaGel® BV disrupts and prevents the formation of biofilms by BV causing bacteria**
- **Biofilm inhibition is a different mechanism from conventional antibiotics and has potential applications beyond BV**
- **Biofilms are thought to play a role in BV recurrence and to contribute to failure rates with conventional antibiotics**





Positive Developments for VivaGel® BV: New FDA Endpoint for BV Treatment &GAIN Act



FDA Primary Endpoint (2012) :

At TOC : 2-3 weeks after treatment ceased

New FDA Primary Endpoint (Updated July 2016^)

At EOT: ~1 week after treatment ceased

Guidance reviews are one of several FDA initiatives under the US GAIN Act* aimed at encouraging and expediting new antimicrobial development…

Janet Woodcock
Director,
FDA Centre for Drug Evaluation
FDA Voice 2014

Starpharma's Two Pivotal Phase 3 Trials of VivaGel® BV (conducted in 2012) both showed highly statistically significant clinical cure at the End of Treatment (EOT) day 9-12 (p<0.0001, p<0.0001) (ie. meet the 2016 FDA Primary Endpoint)

VivaGel® BV showed highly statistically significant clinical cure at day 9-12 (End of Treatment: EOT)

*** The US GAIN Act (Generating Antibiotic Incentives Now) Extends market exclusivity and aims to speed development and FDA review of new antimicrobials**

^Revised FDA Guidance (2016) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510948.pdf

VivaGel® BV: Commercial Status and Plans



Extensive licence negotiations across multiple territories including Europe - global and regional

VivaGel® BV Prevention of Recurrence Phase 3 program



starpharma

SPA granted by FDA

Two double-blind, multi-centre, randomised ~600 patients/trial

USA, Canada, Europe, Asia, Mexico

Primary Endpoint:

Recurrence of BV at or by week 16

SCREENING

Oral Metronidazole 7 days

BASELINE

1% SPL7013 Gel

1:1 randomization

Placebo Gel

WEEK 16

12-weeks follow-up

16-WEEK TREATMENT PERIOD

(DURING WHICH PRIMARY ENDPOINT IS MEASURED)

Dosing regimen: 5g gel every second day at bedtime

Enrolment complete with Top Line Results expected Q2 CY2017



starpharma

Priostar®

Agrochemicals

Priostar® Agrochemicals Dual Strategy



Internal Priostar® Programs

- Application to established agrochemicals (e.g. Glyphosate)
- Self funded
- Returns through licensing
- Patent life extension

Partnered Priostar® Programs

- Application to partner actives – either generic or proprietary
- Platform with broad optionality
- Partner funded development with royalty-based returns
- Adama Priostar® license for improved 2,4-D products
- Patent extension (life-cycle management)

Benefits of Priostar®

Better in the can:

- Solubility enhancement
- Increased loading
- Formulation stability
- Reduction/removal of solvents – "greener" formulations

Better in the field:

- Increased efficacy
- Modification of soil penetration
- Protection of actives
- Patent life extension



Priostar® Agrochemicals Target Market

Global crop protection market dynamics create opportunities for Priostar®

- **Market US$51 billion (2015) and forecast to grow to ~US$59 billion by 2020[1]**
- **Growth underpinned by:**
  - **declining arable land**
  - **greater prevalence of pests and disease**
  - **the requirement for yield improvement**
- **The industry has a low proportion of novel products and high levels of generic competition**
- **There is also increasing focus by regulators and the public on more environmentally friendly products**

Large addressable target markets[1,2]



Fungicides ~US$1.5bn

- A range of actives including:

Propiconazole
Tebuconazole

Herbicides ~US$7.9bn

- A range of actives including:

Glyphosate
Glufosinate-ammonium
2,4-D
Dicamba

Insecticides ~US$1.7bn

- A range of actives including:

Imidacloprid
Deltamethrin

Priostar® has applications in markets worth more than US$10 billion[1,2]

1. Phillips McDougall Industry Overview 2015; 2. 2014 reported sales from Phillips McDougall.

Adama Licenses Priostar® for Novel 2,4-D Products



starpharma

ADAMA

Adama Licenses Starpharma's Priostar for Novel 2,4-D

Melbourne, Australia and Tel-Aviv, Israel: 17 March, 2016 – Starpharma (ASX:SPL; OTCQX: SPHRY) and Adama today announced the licensing by Adama of Starpharma's Priostar® dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US$680 million. The US market in 2014 was worth approximately US$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.

Adama has already undertaken development of a novel and unique 2,4-D product containing the Priostar® dendrimer technology, which is expected to provide better flexibility and weed control benefits to the grower, as well as improved safety. This will allow for on-target application, thus benefiting the environment by reducing the amounts of product required.

- Adama has licensed SPL's Priostar® for novel, improved 2,4-D products for the US market
- Priostar® enhanced product expected to provide better flexibility, weed control and improved safety
- SPL to receive royalties; Adama to fund development and registration
- 2,4-D is the second largest herbicide globally with sales of US$680m

ADAMA

Adama is one of the world's leading crop protection companies with annual sales of US$3.2b and one of the most comprehensive portfolios of differentiated products sold in more than 120 countries. Adama is owned by ChemChina.

CHEMCHINA

"The innovative nature and superior performance of the Priostar® formulations fit well with our strategy to deliver simple and efficient solutions to farmers to help them grow."

Sami Shabtai,
Head of Innovative Development at Adama



Priostar® enhanced glyphosate formulation
Better product performance: increased efficacy

starpharma

Priostar® enhanced glyphosate more effective in hard-to-kill weeds than comparable marketed formulation (glyphosate global sales >US$5B)

Increased efficacy ✓
Early feedback on level of control ✓

Priostar® glyphosate field trial results

- Starpharma has conducted multiple regulatory-compliant field trials, with >16 weed species internationally
- Priostar® product found to be more effective in a number of hard-to-kill weeds than comparable marketed glyphosate product

Key benefits of Priostar® formulation

i. **Better overall effectiveness**
Priostar® formulation leaves only minimal number of weeds alive at end of study while marketed product had >30% survival

ii. **Early feedback of effectiveness to grower**
3 to 4 times as much "brownout" after 5 days than marketed **glyphosate** product (**e.g.**Roundup)



Source: Starpharma field trials.

Priostar® Formulation - major herbicide
Better product performance: increased efficacy

Class of herbicides with global sales of over US$2B in 2015

Trial of Priostar® herbicide^ formulation in rice:

- Increased efficacy (100% weed control) ✓
- Improved crop health ✓
- Potential for increased yield ✓

Selective herbicide applied post-planting

Commercial formulation



Priostar® formulation



Priostar® increased rice seedling density by ~50% over commercial formulation

Commercial formulation causes low crop density and low yield

Priostar® formulation results in significantly higher crop density, increased yield and improved crop health

^ active not yet disclosed pending patent filing



Priostar® Formulation - leading insecticide
Better product performance: removal of solvent

starpharma

Priostar® formulation of leading insecticide^

(global sales >US$350M)

Greener formulation	✓
Reduced formulation odour	✓
Improved crop and operator safety profile	✓
Less solvent released into the environment	✓



Percentage of solvent in formulations



Priostar® reduced solvent by approximately 90%: "greener" formulation

^ active not yet disclosed pending patent filing

Significant market opportunities – multiple options for returns

VivaGel® Portfolio



- Branded global condom market in excess of US$1B
- BV treatment market est. >US$750M
- BV prevention market est. >US$1B

- Returns through licensing agreements
  - Milestones
  - Royalties
  - Product Margin
- Three high value products
- Potential for other commercial licenses

DEP® Drug Delivery Portfolio



- AstraZeneca deal:
  - first product est. US$450M (US$126M + royalties)
  - subsequent products US$93M + royalties
- Docetaxel sales US$3.1B (2012)
- Cabazitaxel sales US$426M (2015)
- Two Targeted DEP® partnerships

- Platform with broad optionality
  - Internal
    - Returns through licensing eg. DEP® docetaxel
    - Milestones and Royalties
  - Partnered
    - Returns through funded development
    - Milestones and Royalties eg. AstraZeneca

Priostar® Agrochemicals



- Priostar® applications in markets worth more than US$10 billion
- 2,4-D is the second largest herbicide globally with sales of US$680M

- Develop value-added, IP-protected agrochemical formulations
- Multiple potential opportunities for revenue streams
  - Royalties and Milestones
  - Manufacturing rights

Outlook

VivaGel® Portfolio



- Launch of VivaGel® BV in Europe, Australia and elsewhere
- Further regulatory approvals for VivaGel® BV
- NDA filing for VivaGel® BV
- Further licenses for VivaGel® BV marketing (multiple territories)
- Complete and report Phase 3 Prevention of BV Recurrence trials
- Launch of VivaGel® condom in Japan
- Further approvals and geographic roll-out of the VivaGel® condom
- Licences based on other applications of the VivaGel® active

DEP® Drug Delivery



- Completion of DEP® docetaxel Phase 1 clinical trial
- Commencement of Phase 2 for DEP® docetaxel
- AZ program developments – milestones, further compounds advanced and expanded licences
- Targeted DEP® program developments and licences
- DEP® cabazitaxel advanced into the clinic
- Other DEP® candidates selected and pre-clinical completed
- Other partnered DEP® deals

Priostar® Agrochemicals



- Progress with Adama 2,4-D Priostar® development and territorial expansion of the licence
- Further Priostar® licenses and other commercial arrangements for access to Priostar®
- Advance internal Priostar® candidates eg. glyphosate and glufosinate ammonium and others
- Licences and pre-registration activities to support commercialisation of internal Priostar® candidates

VivaGel® Portfolio



DEP® Drug Delivery



Priostar® Agrochemicals



www.starpharma.com
investor.relations@starpharma.com